FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2602406293> ?p ?o ?g. }

• W2602406293 endingPage "70" @default.
• W2602406293 startingPage "61" @default.
• W2602406293 abstract "Improving the efficacy of neovascularization is a promising strategy to restore perfusion of ischemic tissues in patients with peripheral arterial disease. The 14q32 microRNA cluster is highly involved in neovascularization. The Mef2a transcription factor has been shown to induce transcription of the microRNAs within this cluster. We inhibited expression of Mef2a using gene-silencing oligonucleotides (GSOs) in an in vivo hind limb ischemia model. Treatment with GSO-Mef2a clearly improved blood flow recovery within 3 days (44% recovery versus 25% recovery in control) and persisted until 14 days after ischemia induction (80% recovery versus 60% recovery in control). Animals treated with GSO-Mef2a showed increased arteriogenesis and angiogenesis in the relevant muscle tissues. Inhibition of Mef2a decreased expression of 14q32 microRNAs miR-329 (p = 0.026) and miR-494 (trend, p = 0.06), but not of other 14q32 microRNAs, nor of 14q32 microRNA precursors. Because Mef2a did not influence 14q32 microRNA transcription, we hypothesized it functions as an RNA-binding protein that influences processing of 14q32 microRNA miR-329 and miR-494. Mef2A immunoprecipitation followed by RNA isolation and rt/qPCR confirmed direct binding of MEF2A to pri-miR-494, supporting this hypothesis. Our study demonstrates a novel function for Mef2a in post-ischemic neovascularization via post-transcriptional regulation of 14q32 microRNAs miR-329 and miR-494. Improving the efficacy of neovascularization is a promising strategy to restore perfusion of ischemic tissues in patients with peripheral arterial disease. The 14q32 microRNA cluster is highly involved in neovascularization. The Mef2a transcription factor has been shown to induce transcription of the microRNAs within this cluster. We inhibited expression of Mef2a using gene-silencing oligonucleotides (GSOs) in an in vivo hind limb ischemia model. Treatment with GSO-Mef2a clearly improved blood flow recovery within 3 days (44% recovery versus 25% recovery in control) and persisted until 14 days after ischemia induction (80% recovery versus 60% recovery in control). Animals treated with GSO-Mef2a showed increased arteriogenesis and angiogenesis in the relevant muscle tissues. Inhibition of Mef2a decreased expression of 14q32 microRNAs miR-329 (p = 0.026) and miR-494 (trend, p = 0.06), but not of other 14q32 microRNAs, nor of 14q32 microRNA precursors. Because Mef2a did not influence 14q32 microRNA transcription, we hypothesized it functions as an RNA-binding protein that influences processing of 14q32 microRNA miR-329 and miR-494. Mef2A immunoprecipitation followed by RNA isolation and rt/qPCR confirmed direct binding of MEF2A to pri-miR-494, supporting this hypothesis. Our study demonstrates a novel function for Mef2a in post-ischemic neovascularization via post-transcriptional regulation of 14q32 microRNAs miR-329 and miR-494." @default.
• W2602406293 created "2017-04-07" @default.
• W2602406293 creator A5000572803 @default.
• W2602406293 creator A5056821715 @default.
• W2602406293 creator A5059802318 @default.
• W2602406293 creator A5063920107 @default.
• W2602406293 creator A5069014764 @default.
• W2602406293 creator A5069577087 @default.
• W2602406293 date "2017-06-01" @default.
• W2602406293 modified "2023-10-01" @default.
• W2602406293 title "Inhibition of Mef2a Enhances Neovascularization via Post-transcriptional Regulation of 14q32 MicroRNAs miR-329 and miR-494" @default.
• W2602406293 cites W144423133 @default.
• W2602406293 cites W1679229092 @default.
• W2602406293 cites W1885003506 @default.
• W2602406293 cites W1973077186 @default.
• W2602406293 cites W1974242642 @default.
• W2602406293 cites W1978636318 @default.
• W2602406293 cites W1991865594 @default.
• W2602406293 cites W2004292360 @default.
• W2602406293 cites W2053551217 @default.
• W2602406293 cites W2072190764 @default.
• W2602406293 cites W2078338047 @default.
• W2602406293 cites W2082922537 @default.
• W2602406293 cites W2095734937 @default.
• W2602406293 cites W2104857427 @default.
• W2602406293 cites W2107139283 @default.
• W2602406293 cites W2109045681 @default.
• W2602406293 cites W2112431248 @default.
• W2602406293 cites W2116631863 @default.
• W2602406293 cites W2145056290 @default.
• W2602406293 cites W2158992273 @default.
• W2602406293 cites W2159974171 @default.
• W2602406293 cites W2167919777 @default.
• W2602406293 cites W2168153711 @default.
• W2602406293 cites W2249452059 @default.
• W2602406293 cites W2277482263 @default.
• W2602406293 cites W2280289381 @default.
• W2602406293 cites W2326623357 @default.
• W2602406293 cites W4231082968 @default.
• W2602406293 doi "https://doi.org/10.1016/j.omtn.2017.03.003" @default.
• W2602406293 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5415962" @default.
• W2602406293 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28624225" @default.
• W2602406293 hasPublicationYear "2017" @default.
• W2602406293 type Work @default.
• W2602406293 sameAs 2602406293 @default.
• W2602406293 citedByCount "15" @default.
• W2602406293 countsByYear W26024062932018 @default.
• W2602406293 countsByYear W26024062932019 @default.
• W2602406293 countsByYear W26024062932020 @default.
• W2602406293 countsByYear W26024062932021 @default.
• W2602406293 countsByYear W26024062932022 @default.
• W2602406293 crossrefType "journal-article" @default.
• W2602406293 hasAuthorship W2602406293A5000572803 @default.
• W2602406293 hasAuthorship W2602406293A5056821715 @default.
• W2602406293 hasAuthorship W2602406293A5059802318 @default.
• W2602406293 hasAuthorship W2602406293A5063920107 @default.
• W2602406293 hasAuthorship W2602406293A5069014764 @default.
• W2602406293 hasAuthorship W2602406293A5069577087 @default.
• W2602406293 hasBestOaLocation W26024062931 @default.
• W2602406293 hasConcept C104317684 @default.
• W2602406293 hasConcept C119056186 @default.
• W2602406293 hasConcept C126322002 @default.
• W2602406293 hasConcept C138885662 @default.
• W2602406293 hasConcept C145059251 @default.
• W2602406293 hasConcept C153911025 @default.
• W2602406293 hasConcept C179926584 @default.
• W2602406293 hasConcept C2778271429 @default.
• W2602406293 hasConcept C2780394083 @default.
• W2602406293 hasConcept C41895202 @default.
• W2602406293 hasConcept C502942594 @default.
• W2602406293 hasConcept C541997718 @default.
• W2602406293 hasConcept C54355233 @default.
• W2602406293 hasConcept C71924100 @default.
• W2602406293 hasConcept C86339819 @default.
• W2602406293 hasConcept C86803240 @default.
• W2602406293 hasConcept C95444343 @default.
• W2602406293 hasConceptScore W2602406293C104317684 @default.
• W2602406293 hasConceptScore W2602406293C119056186 @default.
• W2602406293 hasConceptScore W2602406293C126322002 @default.
• W2602406293 hasConceptScore W2602406293C138885662 @default.
• W2602406293 hasConceptScore W2602406293C145059251 @default.
• W2602406293 hasConceptScore W2602406293C153911025 @default.
• W2602406293 hasConceptScore W2602406293C179926584 @default.
• W2602406293 hasConceptScore W2602406293C2778271429 @default.
• W2602406293 hasConceptScore W2602406293C2780394083 @default.
• W2602406293 hasConceptScore W2602406293C41895202 @default.
• W2602406293 hasConceptScore W2602406293C502942594 @default.
• W2602406293 hasConceptScore W2602406293C541997718 @default.
• W2602406293 hasConceptScore W2602406293C54355233 @default.
• W2602406293 hasConceptScore W2602406293C71924100 @default.
• W2602406293 hasConceptScore W2602406293C86339819 @default.
• W2602406293 hasConceptScore W2602406293C86803240 @default.
• W2602406293 hasConceptScore W2602406293C95444343 @default.
• W2602406293 hasFunder F4320321642 @default.
• W2602406293 hasLocation W26024062931 @default.
• W2602406293 hasLocation W26024062932 @default.
• W2602406293 hasLocation W26024062933 @default.
• W2602406293 hasLocation W26024062934 @default.

• next